Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation.

By F. Danhier, N. Lecouturier, B. Vroman, C. Jérôme, J. Marchand‐Brynaert, Olivier Féron, V. Préat. Journal of Controlled Release, 2009

608 citations recorded by the source corpus.

Subfields: Biomaterials, Molecular Biology, Pharmaceutical Science

View Paper: https://www.semanticscholar.org/paper/52f8126fe4877a28d5db615d867ee19605c1e1dc

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biomaterials

1. F. Danhier
2. Ali Khademhosseini
3. V. Préat
4. Jun Wu

In Molecular Biology

1. F. Danhier
2. Ali Khademhosseini
3. V. Préat
4. Jun Wu

In Pharmaceutical Science

1. Ali Khademhosseini
2. Steven J. Siegel
3. Hirenkumar K. Makadia
4. V. Préat

Citations in the corpus

• Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier (2011, background): “Therefore, the remaining gel becomes more hydrophobic in an aqueous environment, resulting in less water content [20,25–28].”
• PLGA-based nanoparticles: an overview of biomedical applications. (2012, background): “Paclitaxel Preclinical (mice) [98]”
• Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies. (2016, methodology): “PEGylated PLGA copolymer NPs have very high encapsulaion efficiency for paclitaxel, thus leading to high level of apoptotic ancer cells (Danhier et al., 2009).”
• Biocompatibility of engineered nanoparticles for drug delivery. (2013, background): “One area in which they have been widely investigated is in the formulation of the chemotherapeutic drug, paclitaxel (Taxol®) [153].”